Apitoxin Versus Soft Laser for Management of Aphthous Ulceration.

Tanta University

Status

Completed

Conditions

Aphthous Ulceration

Bee Venom Therapy

Apitoxin

Management

Treatments

Device: Low-level laser therapy (LLLT)

Drug: Apitoxin

Study type

Interventional

Funder types

Other

Identifiers

NCT07135609

TUCDREC/300424/ Rsabra.

Details and patient eligibility

About

The current study evaluated the clinical effect and outcome of locally applied bee venom versus low-level laser therapy (LLLT) for the treatment of recurrent aphthous ulceration.

Full description

Recurrent aphthous stomatitis (RAS) is a Painful, idiopathic, and recurrent inflammatory ulceration of the oral cavity.

Despite their widespread use, prolonged or frequent application may result in adverse effects such as oral candida. In recent years, low-level laser therapy (LLLT) has gained attention as an alternative treatment for RAS.

Apitoxin has been used traditionally to treat a variety of conditions, such as arthritis, rheumatism, back pain, cancer, and skin diseases.

Enrollment

60 patients

Sex

All

Ages

15 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age from 15 to 40 years old.
Both sexes.
No current or history of systemic medical problem.
Non-smoker.
Suffering from pain due to recurrent aphthous stomatitis (RAS) ulceration on the oral mucosa with the following characteristics:
Duration of 2 days or less.
The diameter ≥ 4mm
Not been subjected to any treatment modalities for at least four weeks before the beginning of the study.

Exclusion criteria

Presence of other oral mucosal ulcers other than RAS.
Systemic disease that predisposed them to RAS (e.g., Behçet disease).
Systemic medical problems.
Pregnant, lactating, and postmenopausal patients.
Smoker patients.
Systemic or topical treatment for RAS less than four weeks before starting the study.
Any earlier experiences of laser therapy.